272 related articles for article (PubMed ID: 35930304)
21. Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma.
Ng K; Hendifar A; Starodub A; Chaves J; Yang Y; Koh B; Barbie D; Hahn WC; Fuchs CS
Invest New Drugs; 2019 Feb; 37(1):159-165. PubMed ID: 30105668
[TBL] [Abstract][Full Text] [Related]
22. Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study.
Tempero M; Oh DY; Tabernero J; Reni M; Van Cutsem E; Hendifar A; Waldschmidt DT; Starling N; Bachet JB; Chang HM; Maurel J; Garcia-Carbonero R; Lonardi S; Coussens LM; Fong L; Tsao LC; Cole G; James D; Macarulla T
Ann Oncol; 2021 May; 32(5):600-608. PubMed ID: 33539945
[TBL] [Abstract][Full Text] [Related]
23. A phase I/II study of ivaltinostat combined with gemcitabine and erlotinib in patients with untreated locally advanced or metastatic pancreatic adenocarcinoma.
Jo JH; Jung DE; Lee HS; Park SB; Chung MJ; Park JY; Bang S; Park SW; Cho S; Song SY
Int J Cancer; 2022 Nov; 151(9):1565-1577. PubMed ID: 35657348
[TBL] [Abstract][Full Text] [Related]
24. Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: Results of the PANOVA phase 2 study.
Rivera F; Benavides M; Gallego J; Guillen-Ponce C; Lopez-Martin J; Küng M
Pancreatology; 2019 Jan; 19(1):64-72. PubMed ID: 30396819
[TBL] [Abstract][Full Text] [Related]
25. Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE).
Kundranda M; Gracian AC; Zafar SF; Meiri E; Bendell J; Algül H; Rivera F; Ahn ER; Watkins D; Pelzer U; Charu V; Zalutskaya A; Kuesters G; Pipas JM; Santillana S; Askoxylakis V; Ko AH
Ann Oncol; 2020 Jan; 31(1):79-87. PubMed ID: 31912800
[TBL] [Abstract][Full Text] [Related]
26. Anlotinib plus nab-paclitaxel/gemcitabine as first-line treatment prolongs survival in patients with unresectable or metastatic pancreatic adenocarcinoma: a retrospective cohort.
Wu H; Huang N; Zhao C; Hu X; Da L; Huang W; Shen Y; Xiong F; Zhang C
Ann Transl Med; 2022 Mar; 10(6):294. PubMed ID: 35433955
[TBL] [Abstract][Full Text] [Related]
27. Open-label, Phase I Study of Nivolumab Combined with
Wainberg ZA; Hochster HS; Kim EJ; George B; Kaylan A; Chiorean EG; Waterhouse DM; Guiterrez M; Parikh A; Jain R; Carrizosa DR; Soliman HH; Lila T; Reiss DJ; Pierce DW; Bhore R; Banerjee S; Lyons L; Louis CU; Ong TJ; O'Dwyer PJ
Clin Cancer Res; 2020 Sep; 26(18):4814-4822. PubMed ID: 32554514
[TBL] [Abstract][Full Text] [Related]
28. Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma.
Noel M; O'Reilly EM; Wolpin BM; Ryan DP; Bullock AJ; Britten CD; Linehan DC; Belt BA; Gamelin EC; Ganguly B; Yin D; Joh T; Jacobs IA; Taylor CT; Lowery MA
Invest New Drugs; 2020 Jun; 38(3):800-811. PubMed ID: 31297636
[TBL] [Abstract][Full Text] [Related]
29. Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer.
Dotan E; Cardin DB; Lenz HJ; Messersmith W; O'Neil B; Cohen SJ; Denlinger CS; Shahda S; Astsaturov I; Kapoun AM; Brachmann RK; Uttamsingh S; Stagg RJ; Weekes C
Clin Cancer Res; 2020 Oct; 26(20):5348-5357. PubMed ID: 32694153
[TBL] [Abstract][Full Text] [Related]
30. A Modified Regimen of 21-day Nab-Paclitaxel Plus Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer: A Retrospective Real-World Study.
Chang C; Meng L; Li X; Cheng K; Yi C; Peng B; Ma J; Cao D
Cancer Control; 2022; 29():10732748221141233. PubMed ID: 36423238
[TBL] [Abstract][Full Text] [Related]
31. Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma.
Weiss GJ; Blaydorn L; Beck J; Bornemann-Kolatzki K; Urnovitz H; Schütz E; Khemka V
Invest New Drugs; 2018 Feb; 36(1):96-102. PubMed ID: 29119276
[TBL] [Abstract][Full Text] [Related]
32. A phase I dose-escalation study of lenalidomide in combination with gemcitabine in patients with advanced pancreatic cancer.
Ullenhag GJ; Rossmann E; Liljefors M
PLoS One; 2015; 10(4):e0121197. PubMed ID: 25837499
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of gemcitabine plus S-1
Zhu Z; Tang H; Ying J; Cheng Y; Wang X; Wang Y; Bai C
Cancer Biol Med; 2023 Aug; 20(10):765-78. PubMed ID: 37646237
[TBL] [Abstract][Full Text] [Related]
34. Gemcitabine plus nab-paclitaxel followed by maintenance treatment with gemcitabine alone as first-line treatment for older adults with locally advanced or metastatic pancreatic cancer.
Petrioli R; Torre P; Pesola G; Paganini G; Paolelli L; Miano ST; Martellucci I; Francini G; Francini E
J Geriatr Oncol; 2020 May; 11(4):647-651. PubMed ID: 31471168
[TBL] [Abstract][Full Text] [Related]
35. Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer.
Blomstrand H; Scheibling U; Bratthäll C; Green H; Elander NO
BMC Cancer; 2019 Jan; 19(1):40. PubMed ID: 30621618
[TBL] [Abstract][Full Text] [Related]
36. Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer.
Mahipal A; Tella SH; Kommalapati A; Goyal G; Soares H; Neuger A; Copolla D; Kim J; Kim R
Invest New Drugs; 2019 Jun; 37(3):473-481. PubMed ID: 30298303
[TBL] [Abstract][Full Text] [Related]
37. Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial.
Shroff RT; Javle MM; Xiao L; Kaseb AO; Varadhachary GR; Wolff RA; Raghav KPS; Iwasaki M; Masci P; Ramanathan RK; Ahn DH; Bekaii-Saab TS; Borad MJ
JAMA Oncol; 2019 Jun; 5(6):824-830. PubMed ID: 30998813
[TBL] [Abstract][Full Text] [Related]
38. Sequential first-line treatment with nab-paclitaxel/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinical trial.
Assenat E; de la Fouchardière C; Portales F; Ychou M; Debourdeau A; Desseigne F; Iltache S; Fiess C; Mollevi C; Mazard T
ESMO Open; 2021 Dec; 6(6):100318. PubMed ID: 34837745
[TBL] [Abstract][Full Text] [Related]
39. [Nab-Paclitaxel plus Gemcitabine Hydrochloride in Patients with Metastatic or Recurrent Pancreatic Cancer - A Single Institution Experience].
Takeda Y; Katsura Y; Ohmura Y; Sakamoto T; Akiyama Y; Kuwahara R; Morimoto Y; Ishida T; Oneda Y; Murakami K; Naito A; Kagawa Y; Takeno A; Kato T; Tamura S
Gan To Kagaku Ryoho; 2016 Nov; 43(12):1674-1677. PubMed ID: 28133095
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study.
Xu R; Yu X; Hao J; Wang L; Pan H; Han G; Xu J; Zhang Y; Yang S; Chen J; Ying J; Dai G; Li M; Begic D; Lu B; Shen L
BMC Cancer; 2017 Dec; 17(1):885. PubMed ID: 29273007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]